Topical Treatment for Atopic Dermatitis
Recruiting · NCT06244212 · Interventional (participants receive a specific treatment) · Lead sponsor: Wake Forest University Health Sciences
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.
Who can take part
Inclusion criteria
- Diagnosis of skin dermatitis
- Age \> 9
- Ability to return for a one-week clinical studies follow-up
- Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study)
- Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology.
Exclusion criteria
- Patients without the diagnosis of skin dermatitis
- Inability to return for a one week follow up appointment
- Body Surface Area (BSA) affected \<2%
Where it is running
1 location listed across 1 US state.
- Wake Forest University Health Sciences - Winston-Salem, North Carolina, United States